Legal Representation
Attorney
Mitchell E. Radin
USPTO Deadlines 2 active
| Deadline Type | Event Code | Deadline Date | Days Until | Priority | Extension Available |
|---|---|---|---|---|---|
|
MAINTENANCE
Section 8 (6-Year) Declaration Due (Based on registration date 2024-10-29) |
R.PRA | Oct 29, 2030 | 1940 days | Critical | No |
|
MAINTENANCE
Section 8 & 9 (10-Year) Renewal Due (Based on registration date 2024-10-29) |
R.PRA | Oct 29, 2034 | 3401 days | Critical | No |
Next deadline: Section 8 (6-Year) Declaration Due (Based on registration date 2024-10-29)
on October 29, 2030
(1940 days)
Application History
18 events| Date | Code | Type | Description |
|---|---|---|---|
| Oct 29, 2024 | NRCC | E | NOTICE OF REGISTRATION CONFIRMATION EMAILED |
| Oct 29, 2024 | R.PR | A | REGISTERED-PRINCIPAL REGISTER |
| Aug 13, 2024 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Aug 13, 2024 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Jul 24, 2024 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Jul 9, 2024 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Jul 9, 2024 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Jul 9, 2024 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Jul 9, 2024 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Feb 14, 2024 | RFNT | P | REFUSAL PROCESSED BY IB |
| Jan 25, 2024 | RFRR | P | REFUSAL PROCESSED BY MPU |
| Jan 25, 2024 | RFCS | P | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Jan 10, 2024 | RFCR | E | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Jan 9, 2024 | CNRT | R | NON-FINAL ACTION WRITTEN |
| Jan 9, 2024 | DOCK | D | ASSIGNED TO EXAMINER |
| Jul 11, 2023 | MAFR | O | APPLICATION FILING RECEIPT MAILED |
| Jul 7, 2023 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Jul 6, 2023 | REPR | M | SN ASSIGNED FOR SECT 66A APPL FROM IB |
Detailed Classifications
Class 005
Pharmaceutical preparations for the treatment of cancer, immunoproliferative disorders, inflammatory disorders and autoimmune disorders, hematological malignancies, lymphomas, T-cell lymphomas, cutaneous T cell lymphomas, Sezary Syndrome and Mycosis fungoides.
Classification
International Classes
005